Joseph S. Ladd - Academia.edu (original) (raw)

Joseph S. Ladd

Uploads

Papers by Joseph S. Ladd

Research paper thumbnail of Steroid injection, a new gold standard for first-time carpal tunnel syndrome

Pharmacy Today, Mar 1, 2019

Research paper thumbnail of Mortality risk lower in vancomycin vs. metronidazole for CDI, but both agents have their strengths

Pharmacy Today, Apr 1, 2017

Mortality risk lower in vancomycin vs. metronidazole for CDI, but both agents have their strength... more Mortality risk lower in vancomycin vs. metronidazole for CDI, but both agents have their strengths I n its February 2017 issue, JAMA published the largest study to date comparing metronidazole and vancomycin for treatment of Clostridium difficile infection (CDI) in a real-world setting. This retrospective, propensitymatched cohort by Stevens et al. evaluated the risk of recurrence and all-cause 30-day mortality in 10,137 patients receiving metronidazole or vancomycin for treatment of mild to moderate and severe CDI in the U.S. Department of Veterans Affairs health care system from January 1, 2005, to December 31, 2012. While data showed that recurrence rates were similar between groups, risk of mortality was significantly reduced among those treated with vancomycin.

Research paper thumbnail of Guidelines provide direction for I.V. ketamine in pain management

Pharmacy Today, Sep 1, 2018

Research paper thumbnail of Advancements in oncotherapeutics drive positive outcomes in cancer

Pharmacy Today, Jul 1, 2017

Research paper thumbnail of New evidence suggests patients may safely take triptans with SSRIs/SNRIs

Research paper thumbnail of New approval establishes era of ‘tissue-agnostic’ drugs

Research paper thumbnail of ACP says A1C up to 8% is okay in type 2, but other groups object. Now what?

Research paper thumbnail of Ticagrelor may be an option for patients who cannot use aspirin

Pharmacy Today, 2016

Ticagrelor may be an option for patients who cannot use aspirin joseph ladd A fter an acute cereb... more Ticagrelor may be an option for patients who cannot use aspirin joseph ladd A fter an acute cerebrovascular event, many patients rely on clinical judgment to select a secondary prophylaxis regimen. While aspirin therapy is common in this setting, it has its limitations, and the availability of newer antiplatelet agents provides other options.

Research paper thumbnail of Enhancing glycemic management for older adults

Pharmacy Today, 2018

Enhancing glycemic management for older adults A cross-sectional analysis published recently in t... more Enhancing glycemic management for older adults A cross-sectional analysis published recently in the Journal of the American Geriatrics Society found that one-quarter of older adults with type 2 diabetes were tightly controlled and receiving glucose-lowering medications with high risk for hypoglycemia. 1

Research paper thumbnail of Very low LDL-C could reduce heart disease

Research paper thumbnail of Determining duration: How long to prescribe postoperative opioids

Pharmacy Today, Dec 1, 2017

Research paper thumbnail of SIDP calls on pharmacists to lead outpatient antibiotic stewardship

Research paper thumbnail of Antimicrobial stewardship in small hospitals: Breaking down barriers

Pharmacy Today, Nov 1, 2017

Research paper thumbnail of How much is too much? Acetaminophen overuse in the United States

Research paper thumbnail of Increased EHR use has advantages, but also patient safety barriers

Pharmacy Today, Dec 1, 2017

Research paper thumbnail of Adverse events may be associated with two novel drugs, says ISMP

Research paper thumbnail of Three-in-one low-dose tablet shows promise for optimum BP control

Pharmacy Today, 2018

Three-in-one low-dose tablet shows promise for optimum BP control A triple half-dose combination ... more Three-in-one low-dose tablet shows promise for optimum BP control A triple half-dose combination therapy can increase the proportion of patients achieving target blood pressure (BP) goals compared with usual care, according to a recent JAMA study. 1

Research paper thumbnail of Proper use of Kayexalate includes separation from oral medications

Pharmacy Today, Nov 1, 2017

Research paper thumbnail of Oncology breakthroughs give new hope

Pharmacy Today, Feb 1, 2019

Research paper thumbnail of Top-ranked hospitals have increased readmission rates, study finds

Pharmacy Today, Feb 1, 2019

Research paper thumbnail of Steroid injection, a new gold standard for first-time carpal tunnel syndrome

Pharmacy Today, Mar 1, 2019

Research paper thumbnail of Mortality risk lower in vancomycin vs. metronidazole for CDI, but both agents have their strengths

Pharmacy Today, Apr 1, 2017

Mortality risk lower in vancomycin vs. metronidazole for CDI, but both agents have their strength... more Mortality risk lower in vancomycin vs. metronidazole for CDI, but both agents have their strengths I n its February 2017 issue, JAMA published the largest study to date comparing metronidazole and vancomycin for treatment of Clostridium difficile infection (CDI) in a real-world setting. This retrospective, propensitymatched cohort by Stevens et al. evaluated the risk of recurrence and all-cause 30-day mortality in 10,137 patients receiving metronidazole or vancomycin for treatment of mild to moderate and severe CDI in the U.S. Department of Veterans Affairs health care system from January 1, 2005, to December 31, 2012. While data showed that recurrence rates were similar between groups, risk of mortality was significantly reduced among those treated with vancomycin.

Research paper thumbnail of Guidelines provide direction for I.V. ketamine in pain management

Pharmacy Today, Sep 1, 2018

Research paper thumbnail of Advancements in oncotherapeutics drive positive outcomes in cancer

Pharmacy Today, Jul 1, 2017

Research paper thumbnail of New evidence suggests patients may safely take triptans with SSRIs/SNRIs

Research paper thumbnail of New approval establishes era of ‘tissue-agnostic’ drugs

Research paper thumbnail of ACP says A1C up to 8% is okay in type 2, but other groups object. Now what?

Research paper thumbnail of Ticagrelor may be an option for patients who cannot use aspirin

Pharmacy Today, 2016

Ticagrelor may be an option for patients who cannot use aspirin joseph ladd A fter an acute cereb... more Ticagrelor may be an option for patients who cannot use aspirin joseph ladd A fter an acute cerebrovascular event, many patients rely on clinical judgment to select a secondary prophylaxis regimen. While aspirin therapy is common in this setting, it has its limitations, and the availability of newer antiplatelet agents provides other options.

Research paper thumbnail of Enhancing glycemic management for older adults

Pharmacy Today, 2018

Enhancing glycemic management for older adults A cross-sectional analysis published recently in t... more Enhancing glycemic management for older adults A cross-sectional analysis published recently in the Journal of the American Geriatrics Society found that one-quarter of older adults with type 2 diabetes were tightly controlled and receiving glucose-lowering medications with high risk for hypoglycemia. 1

Research paper thumbnail of Very low LDL-C could reduce heart disease

Research paper thumbnail of Determining duration: How long to prescribe postoperative opioids

Pharmacy Today, Dec 1, 2017

Research paper thumbnail of SIDP calls on pharmacists to lead outpatient antibiotic stewardship

Research paper thumbnail of Antimicrobial stewardship in small hospitals: Breaking down barriers

Pharmacy Today, Nov 1, 2017

Research paper thumbnail of How much is too much? Acetaminophen overuse in the United States

Research paper thumbnail of Increased EHR use has advantages, but also patient safety barriers

Pharmacy Today, Dec 1, 2017

Research paper thumbnail of Adverse events may be associated with two novel drugs, says ISMP

Research paper thumbnail of Three-in-one low-dose tablet shows promise for optimum BP control

Pharmacy Today, 2018

Three-in-one low-dose tablet shows promise for optimum BP control A triple half-dose combination ... more Three-in-one low-dose tablet shows promise for optimum BP control A triple half-dose combination therapy can increase the proportion of patients achieving target blood pressure (BP) goals compared with usual care, according to a recent JAMA study. 1

Research paper thumbnail of Proper use of Kayexalate includes separation from oral medications

Pharmacy Today, Nov 1, 2017

Research paper thumbnail of Oncology breakthroughs give new hope

Pharmacy Today, Feb 1, 2019

Research paper thumbnail of Top-ranked hospitals have increased readmission rates, study finds

Pharmacy Today, Feb 1, 2019

Log In